Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant CAPOX followed by CRS+HIPEC for peritoneal carcinomatosis of colorectal origin
2010-020787-37Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin and mitomycin c in peritoneal carcinomatosis (PC) and colorectal cancer (CRC), sponsored by University Medical Center Groningen. Primary endpoint: 30-day or in-hospital mortality following CRS+HIPEC after neoadjuvant chemotherapy. Started Nov 2011; status: active.
02
Drugs
capecitabineoxaliplatinmitomycin c
03
Conditions
peritoneal carcinomatosis (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2010-020787-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020787-37.